Remove 2018 Remove Clinic Remove Diagnostic Remove Disease
article thumbnail

Diagnosing Pediatric Crohn Disease With Radiomic and Clinical Data

Imaging Technology

milla1cf Wed, 08/02/2023 - 19:58 August 2, 2023 — An accepted manuscript published in the American Journal of Roentgenology (AJR) found that deploying a radiomic-based model with T2-weighted MRI data could increase diagnostic accuracy for pediatric Crohn disease (CD). Dillman et al.’s and accuracy of 89.6%. and accuracy of 89.6%.

article thumbnail

Blue Earth Diagnostics Announces Addition of POSLUMA (Flotufolastat F 18) Injection to NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Prostate Cancer

Imaging Technology

POSLUMA is widely available through 36 radiopharmacies in the national network of Blue Earth Diagnostics’ commercial U.S. The addition of POSLUMA to the highly respected NCCN Guidelines is a major milestone for Blue Earth Diagnostics,” said David E. Chief Medical Officer of Blue Earth Diagnostics. Teoh, MBBS, MRCP, FRCR, D.Phil.,

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

U.S. FDA Approves Blue Earth Diagnostics’ POSLUMA (Flotufolastat F 18) Injection, First Radiohybrid PSMA-targeted PET Imaging Agent for Prostate Cancer

Imaging Technology

milla1cf Tue, 05/30/2023 - 19:49 May 30, 2023 — Blue Earth Diagnostics , a Bracco company and recognized leader in the development and commercialization of innovative PET radiopharmaceuticals , today announced U.S. Chief Executive Officer of Blue Earth Diagnostics. Gauden , D.Phil., The adverse reactions reported in ≥0.4%

article thumbnail

Terran Biosciences Receives FDA Clearance for NM-101, the Industry’s First Software for the analysis of Neuromelanin-sensitive MRI

Imaging Technology

We believe this technology could become very important in the clinical workflow of patients with neurological and psychiatric disorders.” While neuromelanin was first described in the 19 th century, researchers have elucidated its possible role as a biomarker for neurological disorders such as Parkinson’s disease in the last two decades.

article thumbnail

ECR: What makes small ovarian lesions light up like a lightbulb?

AuntMinnie

Max Lahaye, MD, of the Netherlands Cancer Institute in Amsterdam presents findings on the clinical impact of dedicated MR staging of ovarian cancer patients during ECR 2024. Finally, the team concluded that MRI appeared to be budget-neutral as a result of ruling out diagnostic laparoscopy in some cases. That's really low.

MRI 110
article thumbnail

Synoptic Reporting Improves Pretreatment CT for Advanced Ovarian Cancer

Imaging Technology

An ovarian cancer synoptic report increased completeness of reporting, facilitating referrer communication and having the potential to improve clinical decision-making,” wrote first author Pamela Causa Andrieu, MD , from the department of radiology at Memorial Sloan Kettering Cancer Center in New York City. Andrieu et al.’s

article thumbnail

Malpractice dos and don'ts: Primer scoops top RSNA award

AuntMinnie

Syphilis: The Reemerging Great Mimicker Clinical manifestations of syphilis are often inconspicuous, and imaging examinations performed for other purposes may lead to overlooking or misdiagnosing syphilis, according to Kano Shintaro, MD, from the Department of Radiology, Jichi Medical University, Tochigi-ken, Japan, and colleagues.